CSIR NMITLI program approves a multi institutional project to develop human monoclonal antibodies (hmAbs) to neutralize SARS-CoV-2

0

08 MAY 2020

CSIR is also supporting new ideas and projects from other academic and industries through its flagship New Millennium Indian Technology Leadership Initiative (NMITLI) program.

Given the importance of deploying multiple strategies against Covid-19, CSIR through NMITLI program has approved a project towards development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team. The team comprises of academic institutes and industry with participants from NCCS, IIT-Indore, PredOmix Technologies Pvt. Ltd. and Bharat Biotech International Ltd (BBIL)

The project aims to generate hmAbs to SARS-CoV-2 from convalescent phase of COVID-19 patients and select high affinity and neutralizing antibodies. The project also aims to anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.BBIL will be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.

Share.

About Author

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Leave A Reply